Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | thyroid hormone receptor, beta | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | photoreceptor-specific nuclear receptor | thyroid hormone receptor, beta | 461 aa | 414 aa | 24.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0208 | 1 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0208 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.008 | 0 | 0.5 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0208 | 1 | 1 |
Treponema pallidum | flavodoxin | 0.008 | 0 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0103 | 0.1841 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0208 | 1 | 1 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0208 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0152 | 0.5614 | 0.4624 |
Trypanosoma cruzi | p450 reductase, putative | 0.0208 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.008 | 0 | 0.5 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0105 | 0.1964 | 0.0151 |
Chlamydia trachomatis | sulfite reductase | 0.0129 | 0.3805 | 0.5 |
Echinococcus multilocularis | Mitotic checkpoint protein PRCC, C terminal | 0.0152 | 0.5614 | 0.292 |
Brugia malayi | FAD binding domain containing protein | 0.0208 | 1 | 1 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0185 | 0.8159 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0129 | 0.3805 | 0.2407 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0208 | 1 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0208 | 1 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0208 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0208 | 1 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0208 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0208 | 1 | 1 |
Leishmania major | cytochrome P450 reductase, putative | 0.0185 | 0.8159 | 0.8159 |
Echinococcus granulosus | Mitotic checkpoint protein PRCC C terminal | 0.0152 | 0.5614 | 0.292 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0208 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0103 | 0.1841 | 0.5 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0208 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0208 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0129 | 0.3805 | 0.3805 |
Schistosoma mansoni | thyroid hormone receptor | 0.0164 | 0.6562 | 0.5786 |
Plasmodium vivax | flavodoxin domain containing protein | 0.0185 | 0.8159 | 0.8159 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0208 | 1 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0208 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.008 | 0 | 0.5 |
Schistosoma mansoni | thyroid hormone receptor | 0.0164 | 0.6562 | 0.5786 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.0185 | 0.8159 | 0.8159 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0129 | 0.3805 | 0.3805 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0208 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0185 | 0.8159 | 0.5 |
Entamoeba histolytica | type A flavoprotein, putative | 0.008 | 0 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0208 | 1 | 1 |
Echinococcus multilocularis | thyroid hormone receptor alpha | 0.0164 | 0.6562 | 0.445 |
Leishmania major | p450 reductase, putative | 0.0208 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.008 | 0 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0208 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 11.2202 um | PUBCHEM_BIOASSAY: Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 25.1189 um | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization. (Class of assay: confirmatory) [Related pubchem assays: 596 ] | ChEMBL. | No reference |
Potency (functional) | 31.6228 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.